Search
Bambuterol
go.drugbank.com/drugs/DB01408InvestigationalBambuterol is a long acting beta-adrenoceptor agonist used in the treatment of asthma. It is a prodrug of terbutaline.
Locnartecan
go.drugbank.com/drugs/DB16186InvestigationalPEN-866 is under investigation in clinical trial NCT03221400 (PEN-866 in Patients With Advanced Solid Malignancies).
Synonyms: Hsp90-targeted sn-38 conjugate pen-866Ramiprilat
go.drugbank.com/drugs/DB14208ExperimentalThe active metabolite of the prodrug Ramipril.
Categories: Agents Acting on the Renin-Angiotensin SystemRhodamine B
go.drugbank.com/drugs/DB16853ExperimentalCategories: Compounds used in a research, industrial, or household settingEW-A-401
go.drugbank.com/drugs/DB05525InvestigationalEW-A-401 is a circle of genetic material (plasmid DNA) that instructs the body to produce a genetically-engineered transcription factor, a protein that regulates expression of genes. … This specific transcription factor has been shown in animal studies to increase expression of the VEGF-A gene, and to promote the growth of new blood vessels.
Synonyms: EW-A-401 DNA Plasmid VectorPRO-542
go.drugbank.com/drugs/DB05793InvestigationalPRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. … PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates.
OBE101
go.drugbank.com/drugs/DB05080ExperimentalOBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. … Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management indications.
Adafosbuvir
go.drugbank.com/drugs/DB14906InvestigationalAdafosbuvir is under investigation in clinical trial NCT02894905 (A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335).
Sirna-027
go.drugbank.com/drugs/DB05896InvestigationalSirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). … VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails.